<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02950467</url>
  </required_header>
  <id_info>
    <org_study_id>15-17825</org_study_id>
    <nct_id>NCT02950467</nct_id>
  </id_info>
  <brief_title>Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors</brief_title>
  <official_title>Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joshua Woolley</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heffter Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>River Styx Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Usona Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stupski Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether psilocybin-assisted group psychotherapy is&#xD;
      a safe and feasible treatment for demoralization in long-term AIDS survivors (LTAS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open-label mixed-methods pilot study of an individual oral psilocybin drug&#xD;
      session combined with ten sessions of an evidence-based, manualized brief group psychotherapy&#xD;
      for existential distress in palliative care patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 5, 2018</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Experienced Treatment-related Adverse Events as Assessed by NIH Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.0</measure>
    <time_frame>Enrollment to 3-month follow up, about 5 months</time_frame>
    <description>Full details of adverse event data are in the Adverse Events module of this ClinicalTrials.gov entry.&#xD;
Adverse events were assessed at every study visit by patient interview. During medication visits, adverse events were also assess by vitals sign monitoring, patient self-report, and adverse events observed by clinicians.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject Recruitment and Retention</measure>
    <time_frame>Duration of study, about 24 months</time_frame>
    <description>Two therapy groups of at least 4 subjects each will complete the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Demoralization Scale-II at End-of-treatment</measure>
    <time_frame>Baseline and end-of-treatment (7 weeks duration)</time_frame>
    <description>Demoralization self-report measure. Minimum = 0. Maximum = 32. Higher scores means a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Demoralization Scale-II at 3-month Follow-up</measure>
    <time_frame>Baseline and 3-month follow-up</time_frame>
    <description>Demoralization self-report measure. Minimum = 0. Maximum = 32. Higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Inventory of Complicated Grief-Revised at End-of-treatment</measure>
    <time_frame>Baseline and end-of-treatment (7 weeks duration)</time_frame>
    <description>Complicated Grief self-report measure. Minimum = 0, Maximum = 76. Higher scores mean worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Inventory of Complicated Grief at 3-month Follow-up</measure>
    <time_frame>Baseline and 3-month follow-up</time_frame>
    <description>Complicated Grief self-report measure. Minimum = 0, Maximum = 76. Higher scores mean worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Center for Epidemiologic Studies Depression Scale-Revised at End-of-treatment</measure>
    <time_frame>Baseline and end-of-treatment (7 weeks duration)</time_frame>
    <description>Depression self-report measure. Minimum = 0. Maximum = 60. Higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Center for Epidemiologic Studies Depression Scale-Revised at 3-month Follow-up</measure>
    <time_frame>Baseline and 3-month follow-up</time_frame>
    <description>Depression self-report measure. Minimum = 0. Maximum = 60. Higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Average Score on Subscales of Group Questionnaire Pre-drug vs Post-drug</measure>
    <time_frame>Mean scores averaged over 2 weeks pre-medication compared to 3 weeks post-medication.</time_frame>
    <description>The Group Questionnaire is a self-report measure with three sub-scales that measure Positive Bonding, Positive Working and Negative Relationship dimensions of the relationships at 3 levels: between group members, between group members and group therapists, and between group members and the group as a whole. Each subscale score is calculated by summation of the ratings across all three levels for each subscale. Positive Bonding scores range from 13 to 91 with higher scores indicating a better outcome. Positive Working scores range 8 to 56 with higher scores indicating a better outcome. Negative Relationship scores range 9 to 63 with higher scores indicating worse outcomes.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change From Baseline in PTSD Checklist 5 at End-of-treatment</measure>
    <time_frame>Baseline and end-of-treatment (7 weeks duration)</time_frame>
    <description>PTSD self-report measure. Minimum = 0. Maximum = 80. Higher scores mean a worse outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in PTSD Checklist 5 at 3-month Follow-up</measure>
    <time_frame>Baseline and 3-month follow-up</time_frame>
    <description>PTSD self-report measure. Minimum = 0. Maximum = 80. Higher scores mean a worse outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in State-Trait Anxiety Inventory (State) at End-of-treatment</measure>
    <time_frame>Baseline and end-of-treatment (7 weeks duration)</time_frame>
    <description>State anxiety self-report measure. Minimum = 0. Maximum = 80. Higher scores mean a worse outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in State-Trait Anxiety Inventory (State) at 3-month Follow-up</measure>
    <time_frame>Baseline and 3-month follow-up</time_frame>
    <description>State anxiety self-report measure. Minimum = 0. Maximum = 80. Higher scores mean a worse outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in State-Trait Anxiety Inventory (Trait) at End-of-treatment</measure>
    <time_frame>Baseline and end-of-treatment (7 weeks duration)</time_frame>
    <description>Trait anxiety self-report measure. Minimum = 0. Maximum = 80. Higher scores mean a worse outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in State-Trait Anxiety Inventory (Trait) at 3-month Follow-up</measure>
    <time_frame>Baseline and 3-month follow-up</time_frame>
    <description>Trait anxiety self-report measure. Minimum = 0. Maximum = 80. Higher scores mean a worse outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in HIV and Abuse Related Shame Inventory at End-of-treatment</measure>
    <time_frame>Baseline and end-of-treatment (7 weeks duration)</time_frame>
    <description>HIV-related shame self-report measure. Minimum = 0. Maximum = 52. Higher scores mean a worse outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in HIV and Abuse Related Shame Inventory at 3-month Follow-up</measure>
    <time_frame>Baseline and 3-month follow-up</time_frame>
    <description>HIV-related shame self-report measure. Minimum = 0. Maximum = 52. Higher scores mean a worse outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in Experiences in Closer Relationships-M16 (Anxiety) at End-of-treatment</measure>
    <time_frame>Baseline and end-of-treatment (7 weeks duration)</time_frame>
    <description>Self-report measure of attachment anxiety. Minimum = 8. Maximum = 56. Higher scores mean worse outcomes.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in Experiences in Closer Relationships-M16 (Anxiety) at 3-month Follow-up</measure>
    <time_frame>Baseline and 3-month follow-up</time_frame>
    <description>Self-report measure of attachment anxiety. Minimum = 8. Maximum = 56. Higher scores mean worse outcomes.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in Experiences in Closer Relationships-M16 (Avoidance) at End-of-treatment</measure>
    <time_frame>Baseline and end-of-treatment (7 weeks duration)</time_frame>
    <description>Self-report measure of attachment avoidance. Minimum = 8. Maximum = 56. Higher scores mean worse outcomes.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in Experiences in Closer Relationships-M16 (Avoidance) at 3-month Follow-up</measure>
    <time_frame>Baseline and 3-month follow-up</time_frame>
    <description>Self-report measure of attachment avoidance. Minimum = 8. Maximum = 56. Higher scores mean worse outcomes.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in McGill Quality of Life Questionnaired-Revised (Overall) at End-of-treatment</measure>
    <time_frame>Baseline and end-of-treatment (7 weeks duration)</time_frame>
    <description>Self-report quality of life measure. Only item A) Overall quality of life. Minimum = 0 (Very bad). Maximum = 10 (Excellent). Higher scores mean better outcomes.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in McGill Quality of Life Questionnaire-Revised (Overall) at 3-month Follow-up</measure>
    <time_frame>Baseline and 3-month follow-up</time_frame>
    <description>Self-report quality of life measure. Only item A) Overall quality of life. Minimum = 0 (Very bad). Maximum = 10 (Excellent). Higher scores mean better outcomes.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in Antiretroviral Medication Adherence Scale at End-of-treatment</measure>
    <time_frame>Baseline and end-of-treatment (7 weeks duration)</time_frame>
    <description>Self-report last-month antiviral medication adherence. Minimum = 0%. Maximum = 100%. Higher scores mean a better outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in Antiretroviral Medication Adherence Scale at 3-month Follow-up</measure>
    <time_frame>Baseline and 3-month follow-up</time_frame>
    <description>Self-report last-month antiviral medication adherence. Minimum = 0%. Maximum = 100%. Higher scores mean a better outcome.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Distress</condition>
  <condition>Depression</condition>
  <condition>Grief</condition>
  <arm_group>
    <arm_group_label>Group therapy plus psilocybin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Psilocybin</intervention_name>
    <description>One individual oral psilocybin treatment session</description>
    <arm_group_label>Group therapy plus psilocybin</arm_group_label>
    <other_name>4-phosphoryloxy-N,N-dimethyltryptamine</other_name>
    <other_name>Indocybin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Modified brief Supportive Expressive Group Therapy</intervention_name>
    <description>Ten sessions of twice-weekly manualized group therapy</description>
    <arm_group_label>Group therapy plus psilocybin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criterion:&#xD;
&#xD;
          -  Older individuals who are long-term AIDS survivors and suffer from moderate-to-severe&#xD;
             demoralization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A physical, neurological or cognitive condition that makes participating in the study&#xD;
             unsafe or unfeasible.&#xD;
&#xD;
          -  Regular psychotropic medication use.&#xD;
&#xD;
          -  Personal or family history of serious mental illness.&#xD;
&#xD;
          -  Severe depression requiring immediate standard-of-care treatment.&#xD;
&#xD;
          -  Exclusion by the clinical judgment of the study investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua Woolley, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brian Anderson, MD,MSc</last_name>
    <role>Study Director</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 26, 2016</study_first_submitted>
  <study_first_submitted_qc>October 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2016</study_first_posted>
  <results_first_submitted>September 21, 2020</results_first_submitted>
  <results_first_submitted_qc>December 13, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 7, 2021</results_first_posted>
  <last_update_submitted>December 13, 2020</last_update_submitted>
  <last_update_submitted_qc>December 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Joshua Woolley</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>HIV/AIDS</keyword>
  <keyword>Demoralization</keyword>
  <keyword>Psilocybin</keyword>
  <keyword>Group therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psilocybin</mesh_term>
    <mesh_term>N,N-Dimethyltryptamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan: Final protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT02950467/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: Final ICF</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT02950467/ICF_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: ICF for Cohorts 2 and 3</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 17, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT02950467/ICF_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan: Pre-modifications related to enrollment exceptions</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 17, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT02950467/Prot_SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from the community 17 July 2017 to 24 August 2018 in the San Francisco Bay Area.</recruitment_details>
      <pre_assignment_details>91 study candidates were screened over the phone, of which 37 were eligible for in-person enrollment evaluations, of which 30 attended an in-person enrollment evaluation and were consented to the study. 18 candidates were found to be eligible for the study, all of whom enrolled in the trial and initiated treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group Therapy Plus Psilocybin</title>
          <description>Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.&#xD;
Psilocybin: One individual oral psilocybin treatment session&#xD;
Modified brief Supportive Expressive Group Therapy: Ten sessions of twice-weekly manualized group therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Open-label Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18">1 participant completed study period but missed some visits due to an adverse event (AE).</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>3-month Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18">All participants completed the safety follow-up assessment, but not all completed outcomes measures.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group Therapy Plus Psilocybin</title>
          <description>Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.&#xD;
Psilocybin: One individual oral psilocybin treatment session&#xD;
Modified brief Supportive Expressive Group Therapy: Ten sessions of twice-weekly manualized group therapy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.2" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Year of HIV/AIDS/GRID Diagnosis</title>
          <description>HIV = Human immunodeficiency virus; AIDS = Acquired immunodeficiency syndrome; GRID = Gay-related immunodeficiency</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1988" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Palliative Performance Scale v2.0</title>
          <description>This clinician-rated scale reports a total score ranging from 0% (Death) to 100% (Full ambulation, normal activity and work, full self-care, etc). Higher scores indicate better performance.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92.8" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Civil status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Single</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Married/Partnered</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Divorced/Separated</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Less than college</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>College or more</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Annual income</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;$50,000</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>â‰¥$50,000</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patients meeting current SCID-5/SCID-5-PD diagnosis</title>
          <description>These diagnostic categories are not mutually exclusive. Patients may meet criteria for more than one diagnosis at one time.&#xD;
SCID = Structured Clinical Interview for DSM-5 SCID-PD = Structured Clinical Interview for DSM-5 - Personality Disorders DSM-5 = Diagnostic and Statistical Manual of Mental Disorders</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Generalized anxiety disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major depressive disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Panic disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Borderline personality disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No SCID-5/SCID-5-PD diagnosis (of those assessed)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PTSD Checklist-5 (PCL-5) &gt;33/80</title>
          <description>PCL-5 is a self-report checklist used to screen for PTSD symptoms. A score &gt;33/80 indicates a possible diagnosis of current PTSD. Higher scores indicated worse PTSD severity.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lifetime: People close to you who have died</title>
          <units>people</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.5" lower_limit="7.25" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lifetime: Times used a classic psychedelic</title>
          <units>instances</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5" lower_limit="3" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Years since last used a classic psychedelic</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20" lower_limit="1" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experienced Treatment-related Adverse Events as Assessed by NIH Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.0</title>
        <description>Full details of adverse event data are in the Adverse Events module of this ClinicalTrials.gov entry.&#xD;
Adverse events were assessed at every study visit by patient interview. During medication visits, adverse events were also assess by vitals sign monitoring, patient self-report, and adverse events observed by clinicians.</description>
        <time_frame>Enrollment to 3-month follow up, about 5 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group Therapy Plus Psilocybin</title>
            <description>Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.&#xD;
Psilocybin: One individual oral psilocybin treatment session&#xD;
Modified brief Supportive Expressive Group Therapy: Ten sessions of twice-weekly manualized group therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Treatment-related Adverse Events as Assessed by NIH Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.0</title>
          <description>Full details of adverse event data are in the Adverse Events module of this ClinicalTrials.gov entry.&#xD;
Adverse events were assessed at every study visit by patient interview. During medication visits, adverse events were also assess by vitals sign monitoring, patient self-report, and adverse events observed by clinicians.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subject Recruitment and Retention</title>
        <description>Two therapy groups of at least 4 subjects each will complete the study</description>
        <time_frame>Duration of study, about 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group Therapy Plus Psilocybin</title>
            <description>Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.&#xD;
Psilocybin: One individual oral psilocybin treatment session&#xD;
Modified brief Supportive Expressive Group Therapy: Ten sessions of twice-weekly manualized group therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Recruitment and Retention</title>
          <description>Two therapy groups of at least 4 subjects each will complete the study</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Enrolled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Completed Safety Assessment at End-of-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Completed Safety Assessment at 3-month follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Demoralization Scale-II at End-of-treatment</title>
        <description>Demoralization self-report measure. Minimum = 0. Maximum = 32. Higher scores means a worse outcome.</description>
        <time_frame>Baseline and end-of-treatment (7 weeks duration)</time_frame>
        <population>intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Group Therapy Plus Psilocybin</title>
            <description>Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.&#xD;
Psilocybin: One individual oral psilocybin treatment session&#xD;
Modified brief Supportive Expressive Group Therapy: Ten sessions of twice-weekly manualized group therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Demoralization Scale-II at End-of-treatment</title>
          <description>Demoralization self-report measure. Minimum = 0. Maximum = 32. Higher scores means a worse outcome.</description>
          <population>intent-to-treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.67" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Demoralization Scale-II at 3-month Follow-up</title>
        <description>Demoralization self-report measure. Minimum = 0. Maximum = 32. Higher scores mean a worse outcome.</description>
        <time_frame>Baseline and 3-month follow-up</time_frame>
        <population>Intent-to-treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Group Therapy Plus Psilocybin</title>
            <description>Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.&#xD;
Psilocybin: One individual oral psilocybin treatment session&#xD;
Modified brief Supportive Expressive Group Therapy: Ten sessions of twice-weekly manualized group therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Demoralization Scale-II at 3-month Follow-up</title>
          <description>Demoralization self-report measure. Minimum = 0. Maximum = 32. Higher scores mean a worse outcome.</description>
          <population>Intent-to-treat analysis</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.78" spread="6.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Inventory of Complicated Grief-Revised at End-of-treatment</title>
        <description>Complicated Grief self-report measure. Minimum = 0, Maximum = 76. Higher scores mean worse outcome.</description>
        <time_frame>Baseline and end-of-treatment (7 weeks duration)</time_frame>
        <population>intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Group Therapy Plus Psilocybin</title>
            <description>Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.&#xD;
Psilocybin: One individual oral psilocybin treatment session&#xD;
Modified brief Supportive Expressive Group Therapy: Ten sessions of twice-weekly manualized group therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Inventory of Complicated Grief-Revised at End-of-treatment</title>
          <description>Complicated Grief self-report measure. Minimum = 0, Maximum = 76. Higher scores mean worse outcome.</description>
          <population>intent-to-treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.22" spread="6.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Inventory of Complicated Grief at 3-month Follow-up</title>
        <description>Complicated Grief self-report measure. Minimum = 0, Maximum = 76. Higher scores mean worse outcome.</description>
        <time_frame>Baseline and 3-month follow-up</time_frame>
        <population>intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Group Therapy Plus Psilocybin</title>
            <description>Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.&#xD;
Psilocybin: One individual oral psilocybin treatment session&#xD;
Modified brief Supportive Expressive Group Therapy: Ten sessions of twice-weekly manualized group therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Inventory of Complicated Grief at 3-month Follow-up</title>
          <description>Complicated Grief self-report measure. Minimum = 0, Maximum = 76. Higher scores mean worse outcome.</description>
          <population>intent-to-treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.06" spread="7.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Center for Epidemiologic Studies Depression Scale-Revised at End-of-treatment</title>
        <description>Depression self-report measure. Minimum = 0. Maximum = 60. Higher scores mean a worse outcome.</description>
        <time_frame>Baseline and end-of-treatment (7 weeks duration)</time_frame>
        <population>intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Group Therapy Plus Psilocybin</title>
            <description>Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.&#xD;
Psilocybin: One individual oral psilocybin treatment session&#xD;
Modified brief Supportive Expressive Group Therapy: Ten sessions of twice-weekly manualized group therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Center for Epidemiologic Studies Depression Scale-Revised at End-of-treatment</title>
          <description>Depression self-report measure. Minimum = 0. Maximum = 60. Higher scores mean a worse outcome.</description>
          <population>intent-to-treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.94" spread="14.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Center for Epidemiologic Studies Depression Scale-Revised at 3-month Follow-up</title>
        <description>Depression self-report measure. Minimum = 0. Maximum = 60. Higher scores mean a worse outcome.</description>
        <time_frame>Baseline and 3-month follow-up</time_frame>
        <population>intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Group Therapy Plus Psilocybin</title>
            <description>Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.&#xD;
Psilocybin: One individual oral psilocybin treatment session&#xD;
Modified brief Supportive Expressive Group Therapy: Ten sessions of twice-weekly manualized group therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Center for Epidemiologic Studies Depression Scale-Revised at 3-month Follow-up</title>
          <description>Depression self-report measure. Minimum = 0. Maximum = 60. Higher scores mean a worse outcome.</description>
          <population>intent-to-treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.89" spread="12.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Average Score on Subscales of Group Questionnaire Pre-drug vs Post-drug</title>
        <description>The Group Questionnaire is a self-report measure with three sub-scales that measure Positive Bonding, Positive Working and Negative Relationship dimensions of the relationships at 3 levels: between group members, between group members and group therapists, and between group members and the group as a whole. Each subscale score is calculated by summation of the ratings across all three levels for each subscale. Positive Bonding scores range from 13 to 91 with higher scores indicating a better outcome. Positive Working scores range 8 to 56 with higher scores indicating a better outcome. Negative Relationship scores range 9 to 63 with higher scores indicating worse outcomes.</description>
        <time_frame>Mean scores averaged over 2 weeks pre-medication compared to 3 weeks post-medication.</time_frame>
        <population>intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Group Therapy Plus Psilocybin</title>
            <description>Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.&#xD;
Psilocybin: One individual oral psilocybin treatment session&#xD;
Modified brief Supportive Expressive Group Therapy: Ten sessions of twice-weekly manualized group therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Average Score on Subscales of Group Questionnaire Pre-drug vs Post-drug</title>
          <description>The Group Questionnaire is a self-report measure with three sub-scales that measure Positive Bonding, Positive Working and Negative Relationship dimensions of the relationships at 3 levels: between group members, between group members and group therapists, and between group members and the group as a whole. Each subscale score is calculated by summation of the ratings across all three levels for each subscale. Positive Bonding scores range from 13 to 91 with higher scores indicating a better outcome. Positive Working scores range 8 to 56 with higher scores indicating a better outcome. Negative Relationship scores range 9 to 63 with higher scores indicating worse outcomes.</description>
          <population>intent-to-treat</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive Bonding (Overall)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.61" spread="4.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive Working (Overall)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="7.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Relationship (Overall)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" spread="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in PTSD Checklist 5 at End-of-treatment</title>
        <description>PTSD self-report measure. Minimum = 0. Maximum = 80. Higher scores mean a worse outcome.</description>
        <time_frame>Baseline and end-of-treatment (7 weeks duration)</time_frame>
        <population>intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Group Therapy Plus Psilocybin</title>
            <description>Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.&#xD;
Psilocybin: One individual oral psilocybin treatment session&#xD;
Modified brief Supportive Expressive Group Therapy: Ten sessions of twice-weekly manualized group therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PTSD Checklist 5 at End-of-treatment</title>
          <description>PTSD self-report measure. Minimum = 0. Maximum = 80. Higher scores mean a worse outcome.</description>
          <population>intent-to-treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9" spread="11.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in PTSD Checklist 5 at 3-month Follow-up</title>
        <description>PTSD self-report measure. Minimum = 0. Maximum = 80. Higher scores mean a worse outcome.</description>
        <time_frame>Baseline and 3-month follow-up</time_frame>
        <population>intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Group Therapy Plus Psilocybin</title>
            <description>Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.&#xD;
Psilocybin: One individual oral psilocybin treatment session&#xD;
Modified brief Supportive Expressive Group Therapy: Ten sessions of twice-weekly manualized group therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PTSD Checklist 5 at 3-month Follow-up</title>
          <description>PTSD self-report measure. Minimum = 0. Maximum = 80. Higher scores mean a worse outcome.</description>
          <population>intent-to-treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.11" spread="13.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in State-Trait Anxiety Inventory (State) at End-of-treatment</title>
        <description>State anxiety self-report measure. Minimum = 0. Maximum = 80. Higher scores mean a worse outcome.</description>
        <time_frame>Baseline and end-of-treatment (7 weeks duration)</time_frame>
        <population>intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Group Therapy Plus Psilocybin</title>
            <description>Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.&#xD;
Psilocybin: One individual oral psilocybin treatment session&#xD;
Modified brief Supportive Expressive Group Therapy: Ten sessions of twice-weekly manualized group therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in State-Trait Anxiety Inventory (State) at End-of-treatment</title>
          <description>State anxiety self-report measure. Minimum = 0. Maximum = 80. Higher scores mean a worse outcome.</description>
          <population>intent-to-treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.56" spread="9.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in State-Trait Anxiety Inventory (State) at 3-month Follow-up</title>
        <description>State anxiety self-report measure. Minimum = 0. Maximum = 80. Higher scores mean a worse outcome.</description>
        <time_frame>Baseline and 3-month follow-up</time_frame>
        <population>intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Group Therapy Plus Psilocybin</title>
            <description>Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.&#xD;
Psilocybin: One individual oral psilocybin treatment session&#xD;
Modified brief Supportive Expressive Group Therapy: Ten sessions of twice-weekly manualized group therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in State-Trait Anxiety Inventory (State) at 3-month Follow-up</title>
          <description>State anxiety self-report measure. Minimum = 0. Maximum = 80. Higher scores mean a worse outcome.</description>
          <population>intent-to-treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" spread="13.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in State-Trait Anxiety Inventory (Trait) at End-of-treatment</title>
        <description>Trait anxiety self-report measure. Minimum = 0. Maximum = 80. Higher scores mean a worse outcome.</description>
        <time_frame>Baseline and end-of-treatment (7 weeks duration)</time_frame>
        <population>intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Group Therapy Plus Psilocybin</title>
            <description>Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.&#xD;
Psilocybin: One individual oral psilocybin treatment session&#xD;
Modified brief Supportive Expressive Group Therapy: Ten sessions of twice-weekly manualized group therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in State-Trait Anxiety Inventory (Trait) at End-of-treatment</title>
          <description>Trait anxiety self-report measure. Minimum = 0. Maximum = 80. Higher scores mean a worse outcome.</description>
          <population>intent-to-treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.06" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in State-Trait Anxiety Inventory (Trait) at 3-month Follow-up</title>
        <description>Trait anxiety self-report measure. Minimum = 0. Maximum = 80. Higher scores mean a worse outcome.</description>
        <time_frame>Baseline and 3-month follow-up</time_frame>
        <population>intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Group Therapy Plus Psilocybin</title>
            <description>Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.&#xD;
Psilocybin: One individual oral psilocybin treatment session&#xD;
Modified brief Supportive Expressive Group Therapy: Ten sessions of twice-weekly manualized group therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in State-Trait Anxiety Inventory (Trait) at 3-month Follow-up</title>
          <description>Trait anxiety self-report measure. Minimum = 0. Maximum = 80. Higher scores mean a worse outcome.</description>
          <population>intent-to-treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.39" spread="10.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in HIV and Abuse Related Shame Inventory at End-of-treatment</title>
        <description>HIV-related shame self-report measure. Minimum = 0. Maximum = 52. Higher scores mean a worse outcome.</description>
        <time_frame>Baseline and end-of-treatment (7 weeks duration)</time_frame>
        <population>intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Group Therapy Plus Psilocybin</title>
            <description>Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.&#xD;
Psilocybin: One individual oral psilocybin treatment session&#xD;
Modified brief Supportive Expressive Group Therapy: Ten sessions of twice-weekly manualized group therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HIV and Abuse Related Shame Inventory at End-of-treatment</title>
          <description>HIV-related shame self-report measure. Minimum = 0. Maximum = 52. Higher scores mean a worse outcome.</description>
          <population>intent-to-treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.83" spread="5.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in HIV and Abuse Related Shame Inventory at 3-month Follow-up</title>
        <description>HIV-related shame self-report measure. Minimum = 0. Maximum = 52. Higher scores mean a worse outcome.</description>
        <time_frame>Baseline and 3-month follow-up</time_frame>
        <population>intent-to-treat (data capture error for 6 participants)</population>
        <group_list>
          <group group_id="O1">
            <title>Group Therapy Plus Psilocybin</title>
            <description>Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.&#xD;
Psilocybin: One individual oral psilocybin treatment session&#xD;
Modified brief Supportive Expressive Group Therapy: Ten sessions of twice-weekly manualized group therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HIV and Abuse Related Shame Inventory at 3-month Follow-up</title>
          <description>HIV-related shame self-report measure. Minimum = 0. Maximum = 52. Higher scores mean a worse outcome.</description>
          <population>intent-to-treat (data capture error for 6 participants)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.25" spread="4.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Experiences in Closer Relationships-M16 (Anxiety) at End-of-treatment</title>
        <description>Self-report measure of attachment anxiety. Minimum = 8. Maximum = 56. Higher scores mean worse outcomes.</description>
        <time_frame>Baseline and end-of-treatment (7 weeks duration)</time_frame>
        <population>intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Group Therapy Plus Psilocybin</title>
            <description>Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.&#xD;
Psilocybin: One individual oral psilocybin treatment session&#xD;
Modified brief Supportive Expressive Group Therapy: Ten sessions of twice-weekly manualized group therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Experiences in Closer Relationships-M16 (Anxiety) at End-of-treatment</title>
          <description>Self-report measure of attachment anxiety. Minimum = 8. Maximum = 56. Higher scores mean worse outcomes.</description>
          <population>intent-to-treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.78" spread="8.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Experiences in Closer Relationships-M16 (Anxiety) at 3-month Follow-up</title>
        <description>Self-report measure of attachment anxiety. Minimum = 8. Maximum = 56. Higher scores mean worse outcomes.</description>
        <time_frame>Baseline and 3-month follow-up</time_frame>
        <population>intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Group Therapy Plus Psilocybin</title>
            <description>Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.&#xD;
Psilocybin: One individual oral psilocybin treatment session&#xD;
Modified brief Supportive Expressive Group Therapy: Ten sessions of twice-weekly manualized group therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Experiences in Closer Relationships-M16 (Anxiety) at 3-month Follow-up</title>
          <description>Self-report measure of attachment anxiety. Minimum = 8. Maximum = 56. Higher scores mean worse outcomes.</description>
          <population>intent-to-treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.33" spread="7.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Experiences in Closer Relationships-M16 (Avoidance) at End-of-treatment</title>
        <description>Self-report measure of attachment avoidance. Minimum = 8. Maximum = 56. Higher scores mean worse outcomes.</description>
        <time_frame>Baseline and end-of-treatment (7 weeks duration)</time_frame>
        <population>intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Group Therapy Plus Psilocybin</title>
            <description>Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.&#xD;
Psilocybin: One individual oral psilocybin treatment session&#xD;
Modified brief Supportive Expressive Group Therapy: Ten sessions of twice-weekly manualized group therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Experiences in Closer Relationships-M16 (Avoidance) at End-of-treatment</title>
          <description>Self-report measure of attachment avoidance. Minimum = 8. Maximum = 56. Higher scores mean worse outcomes.</description>
          <population>intent-to-treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.72" spread="6.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Experiences in Closer Relationships-M16 (Avoidance) at 3-month Follow-up</title>
        <description>Self-report measure of attachment avoidance. Minimum = 8. Maximum = 56. Higher scores mean worse outcomes.</description>
        <time_frame>Baseline and 3-month follow-up</time_frame>
        <population>intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Group Therapy Plus Psilocybin</title>
            <description>Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.&#xD;
Psilocybin: One individual oral psilocybin treatment session&#xD;
Modified brief Supportive Expressive Group Therapy: Ten sessions of twice-weekly manualized group therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Experiences in Closer Relationships-M16 (Avoidance) at 3-month Follow-up</title>
          <description>Self-report measure of attachment avoidance. Minimum = 8. Maximum = 56. Higher scores mean worse outcomes.</description>
          <population>intent-to-treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in McGill Quality of Life Questionnaired-Revised (Overall) at End-of-treatment</title>
        <description>Self-report quality of life measure. Only item A) Overall quality of life. Minimum = 0 (Very bad). Maximum = 10 (Excellent). Higher scores mean better outcomes.</description>
        <time_frame>Baseline and end-of-treatment (7 weeks duration)</time_frame>
        <population>intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Group Therapy Plus Psilocybin</title>
            <description>Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.&#xD;
Psilocybin: One individual oral psilocybin treatment session&#xD;
Modified brief Supportive Expressive Group Therapy: Ten sessions of twice-weekly manualized group therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in McGill Quality of Life Questionnaired-Revised (Overall) at End-of-treatment</title>
          <description>Self-report quality of life measure. Only item A) Overall quality of life. Minimum = 0 (Very bad). Maximum = 10 (Excellent). Higher scores mean better outcomes.</description>
          <population>intent-to-treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in McGill Quality of Life Questionnaire-Revised (Overall) at 3-month Follow-up</title>
        <description>Self-report quality of life measure. Only item A) Overall quality of life. Minimum = 0 (Very bad). Maximum = 10 (Excellent). Higher scores mean better outcomes.</description>
        <time_frame>Baseline and 3-month follow-up</time_frame>
        <population>intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Group Therapy Plus Psilocybin</title>
            <description>Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.&#xD;
Psilocybin: One individual oral psilocybin treatment session&#xD;
Modified brief Supportive Expressive Group Therapy: Ten sessions of twice-weekly manualized group therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in McGill Quality of Life Questionnaire-Revised (Overall) at 3-month Follow-up</title>
          <description>Self-report quality of life measure. Only item A) Overall quality of life. Minimum = 0 (Very bad). Maximum = 10 (Excellent). Higher scores mean better outcomes.</description>
          <population>intent-to-treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" spread="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Antiretroviral Medication Adherence Scale at End-of-treatment</title>
        <description>Self-report last-month antiviral medication adherence. Minimum = 0%. Maximum = 100%. Higher scores mean a better outcome.</description>
        <time_frame>Baseline and end-of-treatment (7 weeks duration)</time_frame>
        <population>intent-to-treat (one participant did not use antiretrovirals)</population>
        <group_list>
          <group group_id="O1">
            <title>Group Therapy Plus Psilocybin</title>
            <description>Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.&#xD;
Psilocybin: One individual oral psilocybin treatment session&#xD;
Modified brief Supportive Expressive Group Therapy: Ten sessions of twice-weekly manualized group therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Antiretroviral Medication Adherence Scale at End-of-treatment</title>
          <description>Self-report last-month antiviral medication adherence. Minimum = 0%. Maximum = 100%. Higher scores mean a better outcome.</description>
          <population>intent-to-treat (one participant did not use antiretrovirals)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.71" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Antiretroviral Medication Adherence Scale at 3-month Follow-up</title>
        <description>Self-report last-month antiviral medication adherence. Minimum = 0%. Maximum = 100%. Higher scores mean a better outcome.</description>
        <time_frame>Baseline and 3-month follow-up</time_frame>
        <population>intent-to-treat (one participant did not use antiretrovirals)</population>
        <group_list>
          <group group_id="O1">
            <title>Group Therapy Plus Psilocybin</title>
            <description>Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.&#xD;
Psilocybin: One individual oral psilocybin treatment session&#xD;
Modified brief Supportive Expressive Group Therapy: Ten sessions of twice-weekly manualized group therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Antiretroviral Medication Adherence Scale at 3-month Follow-up</title>
          <description>Self-report last-month antiviral medication adherence. Minimum = 0%. Maximum = 100%. Higher scores mean a better outcome.</description>
          <population>intent-to-treat (one participant did not use antiretrovirals)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.94" spread="2.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Baseline to 3-month follow-up (5-months post-Baseline)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group Therapy Plus Psilocybin</title>
          <description>Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.&#xD;
Psilocybin: One individual oral psilocybin treatment session&#xD;
Modified brief Supportive Expressive Group Therapy: Ten sessions of twice-weekly manualized group therapy</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NIH DAIDS v2.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Stimulant-induced psychosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>NIH DAIDS v2.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea (post-medication visit)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (post-medication visit)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Motor agitation / Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Unsteady gait / Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Visual changes (complaint)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Headache (post-medication visit)</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety / Anxiety Exacerbation</sub_title>
                <description>(moderate-severe)</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Paranoia / Ideas of Reference</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Thought disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Insomnia (post-medication visit)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Anxiety exacerbation (post-medication visit)</sub_title>
                <description>with methamphetamine lapse</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Post-traumatic stress flashback (post-medication visit)</sub_title>
                <description>with tinnitus, nausea, panic and insomnia</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension (severe, asymptomatic)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypertension (moderate)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michelle Matvey</name_or_title>
      <organization>UCSF</organization>
      <phone>4152214810 ext 24117</phone>
      <email>michelle.matvey@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

